Vericel Corporation focuses on the research, development, and commercialization of advanced cellular therapies and specialty biologics in the United States. The company's flagship products include MACI, an autologous cellularized scaffold product used for the repair of symptomatic cartilage defects of the knee, and Epicel, a permanent skin replacement for patients with deep dermal or full-thickness burns. Additionally, Vericel holds the exclusive North American license for NexoBrid, a biological orphan product used for eschar removal in severe burn patients. Originally founded as Aastrom Biosciences in 1989, the company rebranded as Vericel in 2014 following the acquisition of Sanofi's cell therapy and regenerative medicine business. The company primarily serves healthcare providers, specialized burn centers, and sports medicine practitioners.
